LQ0.F Dextech Medical AB
- Market cap
- EUR 16.6M
- P/E
- -
- P/B
- 10.84x
- ROE
- -34.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Sep 2026.
Is LQ0.F undervalued?
Graham numberThe Graham number of Dextech Medical AB cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Dextech Medical AB fundamental analysis
No fundamental analysis for Dextech Medical AB yet.
Dextech Medical AB stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Dextech Medical AB
DexTech Medical AB (publ) engages in the development of drug candidates with application in urological oncology, primarily prostate cancer in Sweden. The company's lead candidate, OsteoDex, which has completed a phase IIb clinical trial for the treatment of bone metastases in castration-resistant prostate cancer, as well as in preclinical stage to treat breast and lung cancer, as well as multiple myeloma. The company is also developing SomaDex, a medication candidate that is…
Full company profileDextech Medical AB financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Dextech Medical AB annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 3.12M | 8.71M | 5.39M | 3.22M | 5.01M | 1.14M |
| Operating Income | -5.27M | -4.94M | -5.55M | -5.32M | -6.65M | -5.95M |
| EBITDA | - | -1.87M | -1.86M | -1.10M | -1.56M | -5.95M |
| Net Income | -5.27M | -4.59M | -4.71M | -4.84M | -6.46M | -5.82M |
| EPS | -0.29 | -0.25 | -0.25 | -0.26 | -0.35 | -0.31 |
| Balance Sheet | ||||||
| Total Assets | 39.6M | 35.0M | 30.6M | 25.1M | 19.0M | 17.1M |
| Total Liabilities | 712K | 718K | 980K | 337K | 650K | 265K |
| Shareholders' Equity | 38.9M | 34.3M | 29.6M | 24.8M | 18.3M | 16.8M |
| Cash & Short-term Investments | 35.5M | 25.2M | 19.0M | 14.7M | 8.63M | 7.68M |
| Cash Flow | ||||||
| Operating Cash Flow | -2.00M | -1.55M | -808K | -1.11M | -1.07M | -2.68M |
| Capital Expenditure | 3.12M | 8.71M | 5.39M | 3.22M | 5.01M | 0.00 |
| Free Cash Flow | -5.12M | -10.3M | -6.19M | -4.33M | -6.08M | -2.68M |
| Ratios | ||||||
| ROE | -13.6% | -13.4% | -15.9% | -19.6% | -35.3% | -34.5% |
| ROA | -13.3% | -13.1% | -15.4% | -19.3% | -34.1% | -34.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
Dextech Medical AB dividends
Dextech Medical AB has not paid dividends in the last 5 fiscal years.
Who owns Dextech Medical AB
- Insiders 61.46%
- Institutions 0.00%
- Public & others 38.54%
- Shares outstanding 18.5M
- Free float 8.31M
Dextech Medical AB company profile
- Company name
- Dextech Medical AB
- Ticker
- LQ0.F
- ISIN
- SE0005881489
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1
- Fiscal year end
- June
- Address
- Dag HammarskjOelds VAeg 34A, Uppsala, Sweden, 752 37
- Phone
- 46 7 07 10 47 88
- Website
- dextechmedical.com
About Dextech Medical AB
DexTech Medical AB (publ) engages in the development of drug candidates with application in urological oncology, primarily prostate cancer in Sweden. The company's lead candidate, OsteoDex, which has completed a phase IIb clinical trial for the treatment of bone metastases in castration-resistant prostate cancer, as well as in preclinical stage to treat breast and lung cancer, as well as multiple myeloma. The company is also developing SomaDex, a medication candidate that is based on hormone, somatostatin, or the treatment of acromegaly, neuroendocrine tumors, and palliative care in advanced prostate cancer; and PSMA-binding conjugates for the target-specific treatment of mCRPC that overexpresses prostate specific membrane antigen (PSMA). In addition, the company offers GuaDex, a technology platform for new dextran-based drug candidates. DexTech Medical AB (publ) was incorporated in 2004 and is based in Uppsala, Sweden.
Dextech Medical AB management
3- Mr. Anders Ragnarsson Holmberg M.D.Founder, CEO, MD, Director Member of Executive Board · born 1951
- Mr. Gösta LundgrenCFO & Head of Investor Relations · born 1955
- Dr. Sten Nilsson M.D., Ph.D.Member of Executive Board · born 1948